IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a significant decline in short interest in July. As of July 15th, there was short interest totaling 20,789 shares, a decline of 40.8% from the June 30th total of 35,117 shares. Based on an average trading volume of 53,283 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of IN8bio in a research report on Thursday, June 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, IN8bio presently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On IN8bio

A number of institutional investors have recently bought and sold shares of the business. HRT Financial LP acquired a new position in shares of IN8bio in the 4th quarter valued at about $34,000. Captrust Financial Advisors acquired a new stake in shares of IN8bio during the fourth quarter worth approximately $43,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of IN8bio during the fourth quarter worth approximately $56,000. Citadel Advisors LLC acquired a new stake in shares of IN8bio during the third quarter worth approximately $54,000. Finally, Two Sigma Investments LP purchased a new position in IN8bio during the third quarter valued at approximately $107,000. 92.05% of the stock is currently owned by institutional investors and hedge funds.

IN8bio Stock Down 4.9%

Shares of NASDAQ:INAB opened at $1.03 on Friday. The company’s fifty day moving average is $1.41 and its two-hundred day moving average is $1.62. The company has a market cap of $10.12 million, a P/E ratio of -0.39 and a beta of 0.22. IN8bio has a 12-month low of $0.96 and a 12-month high of $2.73.

IN8bio (NASDAQ:INAB) last issued its earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.33. Equities research analysts anticipate that IN8bio will post -1.53 earnings per share for the current year.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.